Thursday, August 14, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including Merck & Co.

Manufacturing in Ireland has long helped many American drug companies pay lower taxes. But that strategy was designed for a ...

M&A deals announced worldwide in July included a rail merger, which is the largest transaction in the past 12 months based on ...

But rising Chinese import tariffs due to the trade war with the U.S. and longer-term concerns about costs or access are ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Drug companies have formed a new group to present lawmakers with research on what the industry sees as the negative impacts ...

Merck has begun the 8% reduction of its workforce—an initiative that the company revealed two weeks ago—with the dismissal of ...

If you have decades to go before you retire, you want to make sure you own companies that know how to survive and thrive.

Merck & Co., Inc. recently reported robust earnings, yet the market response was lukewarm. Investors overlooked several positive aspects beneath the surface. Unusual expenses, totaling US$4.2 billion, ...

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...

The research, done in mice and in human cells, shows that a protein called STUB1 restrains the immune system’s elite ...